Radek Špíšek to become new CEO of SOTIO

February 27, 2018
Source: Press Release, Prague

SOTIO, a biotechnology company belonging to the PPF Group, announces today the appointment of Professor Radek Špíšek as Chief Executive Officer. Effective from March 1, 2018, he will replace the current CEO, Ladislav Bartoníček, who will remain active within SOTIO’s top management and will replace Radek Špíšek on the company’s Supervisory Board. The appointment of Radek Špíšek as the CEO will ensure continuity in the company’s management and strategic goals. 

Ladislav Bartoníček, who is also a PPF Group shareholder, commented: “Within the span of a few years, SOTIO has been transformed from a small start-up founded on a single product to an international biotechnology company. Today, SOTIO is an integrated company that possesses the necessary capabilities for the research, clinical development, manufacturing and future commercialization of a variety of technologies. New projects launched with partner companies such as Cytune, NBE-Therapeutics, and LDC, are approaching the clinical development stage. Radek’s appointment strengthens the continuity of SOTIO’s strategy and at the same time positions SOTIO well for the development of a broad and diverse pipeline in the near future.”

Ladislav Bartoníček has been SOTIO’s Chief Executive Officer since the beginning of 2014. Radek Špíšek is a co-founder of SOTIO. Since 2010 he has been a member of the company’s top management as well as overseeing research and manufacturing. He has many years of experience in the field of immunotherapy research and clinical development of new cancer therapies.

Radek Špíšek is a graduate of the 1st Medical Faculty of Charles University, and completed postgraduate study in the field of immunology. From 2000 to 2002, he worked at the Institute de Biologie at the University of Nantes in France, followed by three years of research in the team of Ralph Steinmann, a laureate of the Nobel Prize for Physiology or Medicine, at the Department of Tumor Radiology of the Rockefeller University in New York. Radek is a renowned researcher in the field of tumor immunology and antitumor immunotherapy. He is a professor of medical immunology at the 2nd Medical Faculty of Charles University in Prague.